bsm-10808M [Primary Antibody]
G-CSF(2C7) Monoclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Mouse

Target Protein: G-CSF

Clonality: Monoclonal

Isotype: IgG

Entrez Gene: 1440

Swiss Prot: P09919

Source: KLH conjugated synthetic peptide derived from human G-CSF

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C for 12 months.

Background:

Granulocyte-colony stimulating factor (G-CSF) is a growth factor and an essential cytokine belonging to the CSF family of hormone-like glycoproteins that regulate haematopoietic cell proliferation and differentiation. G-CSF was isolated initially as a factor supporting the growth of colonies of granulocytes in soft agar cultures. Cells of the monocyte/macrophage lineage are among the most prominent sources of G-CSF, but this factor can also be produced by normal cells of mesodermal origin, including vascular endothelial cells, fibroblasts, and mesothelial cells. Production of G-CSF can be induced in vitro in these cells by a wide variety of stimulatory agents, including LPS, TNF, IL-1, IL-3, I L-4, and IFN-Gamma. G-CSF is likely to play a role in the basal regulation of neutrophil production, and also functions as a primary regulatory factor controlling the neutrophil response to inflammatory stimuli. Furthermore, G-CSF exhibits other biological activities besides the proliferative effects, since G-CSF appears to modulate the distribution of neutrophils and progenitor cells within the body.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)

Predicted Molecular Weight: 19 kDa


Cross Reactive Species: Human
Mouse

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Lane 1: Recombinant human G-CSF protein, His(bs-42107P) probed with G-CSF Monoclonal Antibody, Unconjugated (bsm-10808M) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.